Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 15/20 | 0.74 |
| ▸ | IDH1 | O75874 | 10/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763409 | 0.86 | IDH2 (0.79) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15094193 | 0.86 | IDH2 (0.79) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102211 | 0.85 | IDH1 (0.84) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL28897972 | 0.85 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18214303 | 0.84 | IDH2 (0.65) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL21958254 | 0.83 | IDH2 (0.75) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL29360046 | 0.83 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL15102202 | 0.83 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL30524664 | 0.83 | IDH1 (0.50) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL16370029 | 0.83 | IDH1 (0.50) | IDH2IDH1ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363115-A2 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210163426-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-06-03 | — | — | US | disclosed |
| WO-2019047909-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363115-A2 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | CYP4F11, CYP11B1, CYP11B2 | IDH2 1181/4885IDH1 605/4885ABCB11 73/4885 |
| US-20210163426-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | CYP4F11, CYP11B1, CYP11B2 | IDH2 1937/4885IDH1 980/4885ABCB11 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.